Keywords: Renal cell carcinoma; European Association of Urology guidelines; Nivolumab; Ipilimumab;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Checkpoint inhibitors; Ipilimumab; Pembrolizumab; Nivolumab; Autoimmunity; Rheumatic manifestations; Psoriatic arthritis; Rheumatoid arthritis; Eosinophilic fasciitis; Sarcoidosis;
Keywords: Thyroiditis; PD-1; CTLA-4; Ipilimumab; Nivolumab; Cytology;
Keywords: cardio-oncology; checkpoint inhibitor; ipilimumab; myocarditis; nivolumab; pembrolizumab; anti-CTLA4; anti-cytotoxic T-lymphocyte-associated protein 4; anti-PD1; anti-programmed cell death protein 1; anti-PDL1; anti-programmed death-ligand 1; AUC; area un
Keywords: Urothelial carcinoma; Immune-checkpoint inhibitors; Pembrolizumab; Atezolizumab; Avelumab; Durvalumab; Nivolumab; Ipilimumab; Combination therapy;
Keywords: Cervical cancer; Immune check-point; Immunotherapy; CTLA-4; PD-1; Ipilimumab; Pembrolizumab; Nivolumab;
Keywords: Renal cell carcinoma; Cabozantinib; Nivolumab; Ipilimumab; Bevacizumab; Atezolizumab;
Keywords: Checkpoint immunotherapy; CTLA-4, PD-1; Ipilimumab; Nivolumab; Neuropathy; Guillain-Barre;
Keywords: immune checkpoint blockade; ipilimumab; nivolumab; squamous cell carcinoma; cSCC; cutaneous squamous cell carcinoma; DICB; dual immune checkpoint blockade; ICB; immune checkpoint blockade; ipi/nivo; ipilimumab and nivolumab; mcSCC; metastatic cSCC;
Keywords: Melanoma; Checkpoint inhibitors; Ipilimumab; Nivolumab; Pembrolizumab; Immune-related adverse events;
Keywords: Immune-related adverse events; Hypophysitis; Thyroiditis; Ipilimumab; Nivolumab; Melanoma;
Keywords: advanced melanoma; cost-effectiveness; ipilimumab; pembrolizumab;
Keywords: cabozantinib; depigmentation; dyspigmentation; hyperpigmentation; hypopigmentation; imatinib; ipilimumab; nivolumab; pazopanib; pembrolizumab; pigmentary; repigmentation; sorafenib; sunitinib; vitiligo; AE; adverse event; Bcr-abl; breakpoint cluster regio
Keywords: Atezolizumab; ipilimumab; nivolumab; pembrolizumab; treatment-related death; tremelimumab;
Keywords: Melanoma; Ipilimumab; Adjuvant therapy; Randomised trials; Survival;
Keywords: Checkpoint inhibitors; Ipilimumab; Pembrolizumab; Nivolumab; Organ transplantation; Rejection;
Keywords: Gynecologic mucosal melanoma; Vaginal melanoma; Cervical melanoma; Ipilimumab; Immunotherapy; Radiation therapy
Keywords: Bevacizumab; glioblastoma; high grade glioma; immunotherapy; ipilimumab;
Keywords: Programmed cell death 1; PD-1; PDCD1; anti-PD-1 antibody; PD-1 inhibitor; nivolumab; pembrolizumab; acute interstitial nephritis (AIN); acute kidney injury (AKI); non-small cell lung cancer (NSCLC); advanced melanoma; ipilimumab; immune checkpoint inhib
Keywords: Biomarkers; Sipuleucel-T; Ipilimumab; Nivolumab; Ki-67; MDSCs; Tregs; ELISpot; Renal cell; Prostate cancer; Bladder cancer; CTCs; PSA; PSMA; IL-2; Immunoscore; Cytokines
Keywords: Immune-checkpoint inhibitors; Immune-related adverse events; Ipilimumab; Nivolumab; Pembrolizumab; Melanoma; Lung cancer; Renal cancer
Keywords: acute kidney injury; ipilimumab; nivolumab; pembrolizumab;
Keywords: Fatigue; ipilimumab; nivolumab; pembrolizumab; tremelimumab;
Keywords: Melanoma; Nanotechnology; Nanoparticles; Chemotherapy; Immunotherapy; Drug resistance; Vemurafenib; Dabrafenib; Ipilimumab;
Keywords: CD8 cytotoxic T lymphocyte; cytokine; interleukin-2 (IL-2); ipilimumab; PD1 blockade
Keywords: BRAF; v-raf murine sarcoma viral oncogene homolog; MEK; MAP kinase-ERK kinase; KIT; V-KIT Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; CTLA-4; cytotoxic T-lymphocyte-associated antigen 4; PD-1/PD-L1; programmed death-1/ programmed death-1 li
Keywords: Melanoma; Europe; Ipilimumab; Immunotherapy; Chemotherapy; Targeted therapy; Combination;
Keywords: AKT inhibitor; autoimmune adverse effects; autoimmune dermopathies; B-RAF; dabrafenib; dermatitis; dual inhibitor; dysgeusia; everolimus; hair loss; hedgehog signaling pathway; immunotherapy; immune-related toxicities; ipilimumab; keratoacanthoma; keratos
Keywords: Immuno-oncology; T-cell receptors; Novel evaluation criteria; Ipilimumab; Nivolumab; Combinations; AE; Adverse events; APC; Antigen-presenting cell; BMS; Bristol-Myers Squibb; CR; Complete response; CTLA-4; Cytotoxic T-lymphocyte antigen 4; DTIC; Dacarbaz
Keywords: Ipilimumab; Tremelimumab; Nivolumab; Immunotherapy; Checkpoint inhibitor; Anti-PD-1; Anti-PD-L1; Anti-CTLA4;
Keywords: Immunotherapy; Non-small cell lung cancer; PD-L1; CTLA-4; Ipilimumab; Nivolumab;
Keywords: Melanoma; Brain metastases; Vemurafenib; Dabrafenib; BRAF; Ipilimumab; Blood brain barrier;
Keywords: Metastatic melanoma; Immunotherapy; CTLA-4; Blocking antibodies; Tremelimumab; Ipilimumab; Anti-PD1;
Keywords: Ipilimumab; Colitis; Adverse event; Infliximab; MelanomaIpilimumab; Colitis; Efecto adverso; Infliximab; Melanoma
Ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum evaluated using 3D fluid-attenuated inversion recovery
Keywords: Ipilimumab; Hypophysitis; Optic tract; 3D FLAIR; Melanoma;
Dose-dependent toxicity of ipilimumab in metastatic melanoma
Keywords: Melanoma; Immune checkpoint inhibition; Ipilimumab; Toxicity;
Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients
Keywords: Melanoma; Checkpoint inhibitor; Ipilimumab; Nivolumab; Switching;
Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: A systematic review
Keywords: Abscopal effect; Radiotherapy; Immunotherapy; CTLA-4; Ipilimumab;
Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1
Keywords: Melanoma; Immunotherapy; Ipilimumab; Cancer/testis antigen; NY-ESO-1;
The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies
Keywords: Clinical trial design; FRACTION; Combination immuno-oncology therapy; Platform trial; Nivolumab; Ipilimumab;
Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab
Keywords: MDSC; Melanoma; ATRA; Ipilimumab; Randomized Clinical Trial; Immunotherapy;
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate rece
Keywords: Alefacept; Fingolimod; Infection; Ipilimumab; Natalizumab; Nivolumab; Pembrolizumab; Progressive multifocal leukoencephalopathy; Proteasome inhibitors; Vedolizumab;
DNA mismatch repair in cancer
Keywords: 5-FU; 5-fluorouracil; bMMRD; Biallelic mismatch repair deficiency; CD28; cluster of differentiation 28; CIN; Chromosomal instable; CR; complete response; CRC; colorectal cancer; CTL; cytotoxic T-lymphocytes; CTLA-4; cytotoxic T lymphocyte antigen-4; DFS;
Nephrotic Syndrome With Cancer Immunotherapies: A Report of 2 Cases
Keywords: Oncologic immunotherapies; pembrolizumab; acute kidney injury (AKI); ipilimumab; nephrotic syndrome; nephrotic-range proteinuria; podocytopathy; minimal change disease; case reports;
Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT
Keywords: FDG; PET-CT; melanoma; ipilimumab; immune-related adverse events;
Nivolumab and ipilimumab in the treatment of metastatic renal cell carcinoma. Report of two patients
Keywords: Immunotherapy; Metastatic renal cell carcinoma; Nivolumab; Ipilimumab;
Current PerspectiveThe 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients
Keywords: Melanoma; Adjuvant therapy; Randomised trials; Nivolumab; Ipilimumab; Dabrafenib; Trametinib;
Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma
Keywords: Advanced melanoma; Adolescents; Ipilimumab; Immune-mediated adverse reaction; Overall survival; Progression-free survival;
Pembrolizumab's non-cross resistance mechanism of action successfully overthrown ipilimumab
Keywords: Metastatic skin cancer; Programmed cell death-1; Non-cross resistant; BRAF inhibitors; Ipilimumab; Pembrolizumab;
Copy number variation analysis and methylome profiling of a GNAQ-mutant primary meningeal melanocytic tumor and its liver metastasis
Keywords: Meningeal melanocytic tumor; Meningeal melanoma; Liver metastasis; GNAQ; Copy number variations; Methylation; Ipilimumab;